Pulmonary function tests: High rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease

Arthritis and Rheumatology

Volumn 67, Issue 12, 2015, Pages 3256-3261

  Suliman, Yossra A ^a,b   Dobrota, Rucsandra ^b,d   Huscher, Dörte ^c   Nguyen Kim, Thi D L ^b   Maurer, Britta ^b   Jordan, Suzana ^b   Speich, Rudolf ^b   Frauenfelder, Thomas ^b   Distler, Oliver ^b  

^a ASSIUT UNIVERSITY   (Egypt)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

CENTROMERE ANTIBODY; SCL 70 ANTIBODY; ANTINUCLEAR ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE SCLERODERMA; DIFFUSING CAPACITY FOR CARBON MONOXIDE; EARLY DIAGNOSIS; EVIDENCE BASED PRACTICE; FALSE NEGATIVE RESULT; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT PARAMETERS; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; COHORT ANALYSIS; COMPLICATION; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; IMMUNOLOGY; LABORATORY DIAGNOSIS; LUNG DIFFUSION CAPACITY; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PULMONARY FIBROSIS; RADIOGRAPHY; SCLERODERMA, SYSTEMIC; STATISTICAL MODEL; VERY ELDERLY; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; COHORT STUDIES; DIAGNOSTIC ERRORS; EARLY DIAGNOSIS; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; LOGISTIC MODELS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TOTAL LUNG CAPACITY; VITAL CAPACITY;

EID: 84948406336     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39405     Document Type: Article

References (15)

1. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al., Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
2. Steele R, Hudson M, Lo E, Baron M, on behalf of the Canadian Scleroderma Research Group. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64: 519-24.
3. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al., Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
4. Wells AU, Margaritopoulos GA, Antoniou KM, Denton C., Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med 2014; 35: 213-21.
5. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, et al., Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2014; 69: 428-36.
6. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
7. American College of Radiology. ACR practice guideline for the performance of high-resolution computed tomography (HRCT) of the lungs in adults. Revised 2010 (Resolution 43). URL: http://doseoptimization.jacr.org/Content/PDF/Lungs.pdf.
8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al., Standardisation of spirometry. Eur Respir J 2005; 26: 319-38.
9. Villalba WO, Sampaio-Barros PD, Pereira MC, Cerqueira EM, Leme CA Jr, Marques-Neto JF, et al., Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007; 131: 217-22.
10. Vonk MC, Broers B, Heijdra YF, Ton E, Snijder R, van Dijk AP, et al., Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis 2009; 68: 961-5.
11. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al., Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52: 155-60.
12. Gohari Moghadam K, Gharibdoost F, Parastandechehr G, Salehian P., Assessments of pulmonary involvement in patients with systemic sclerosis. Arch Iran Med 2011; 14: 22-6.
13. Remy-Jardin M, Giraud F, Remy J, Copin MC, Gosselin B, Duhamel A., Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993; 189: 693-8.
14. Doyle TJ, Hunninghake GM, Rosas IO., Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012; 185: 1147-53.
15. Frauenfelder T, Winklehner A, Nguyen TD, Dobrota R, Baumueller S, Maurer B, et al., Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study. Ann Rheum Dis 2014; 73: 2069-73.